Clinical Research Directory
Browse clinical research sites, groups, and studies.
12 clinical studies listed.
Filters:
Tundra lists 12 Refractory Epilepsy clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07668856
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials
The goal of this clinical trial is to learn if cannabidiol ("CBD-oil") works to treat severe epilepsy in children. It will also learn about the safety of cannabidiol. The main questions it aims to answer are: * Does cannabidiol lower the number of seizure in children with severe epilepsy? * Does cannabidiol effect other outcomes such as behaviour, sleep, communication, activities? * What medical problems do participants have when taking cannabidiol? Researchers will compare cannabidiol to a placebo (a look-alike oil that contains no cannabidiol) to see if drug cannabidiol works to treat severe epilepsy. All participants will receive both the cannabidiol and the placebo during different periods. At the end of the trial, we will evaluate for each patient seperately, whether seizures were less or more frequent during cannabidiol periods or placebo periods, to see what works best for every patient seperately. Participants will: * Register their seizures in a digital application during 4 to 6 periods. During these periods, CBD oil of placebo will be provided * Take CBD oil during 2 to 3 periods. One period will last around 7 weeks. * Also take placebo oil during the other 2 to 3 periods * Have a blood test every 7 weeks to monitor for safety and possible adverse effects * Visit the clinic once every 15 weeks for checkups and tests * Fill in questionnaires about quality of life, functioning, sleep, behaviour, epilepsy severity every 7 weeks.
Gender: All
Ages: 1 Year - 18 Years
Updated: 2026-06-25
1 state
NCT06387186
Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy
The main purpose of this study is to evaluate the safety and tolerability of a Leucine-Enriched Essential Amino Acid (LEAA) Powder as an add-on to a classic ketogenic diet (KD) in pediatric and adult patients with refractory epilepsy.
Gender: All
Ages: 2 Years - Any
Updated: 2026-05-22
1 state
NCT06425029
Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application
This is a prospective, placebo-controlled, double-blinded randomized study of self-administered auditory intervention in a naturalistic home environment.
Gender: All
Ages: 18 Years - Any
Updated: 2026-05-20
2 states
NCT06141668
Optimal Stimulation Parameters to Disrupt Epileptiform Activity
Open-loop electrical stimulation has been found to reduce spike activity and seizures, but determining the optimal parameters to achieve these effects requires a brute force trial-and-error approach that relies on subjective physician discretion. We will compare the performance of stimulation parameters identified in rodent models to the recommended parameters for neuromodulation used in clinical practice.
Gender: All
Updated: 2026-04-30
1 state
NCT07305311
Characterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG
The prospective study aims to characterize the network-specific modulatory effects of piriform cortex stimulation in patients undergoing stereotactic EEG for drug-resistant epilepsy. Using multimodal data, it seeks to link stimulation-evoked electrophysiological responses across brain networks with clinical outcomes, to inform targeted neuromodulation therapies.
Gender: All
Ages: 14 Years - 65 Years
Updated: 2025-12-26
1 state
NCT05493722
Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy
Deep brain stimulation (DBS) is used to treat epilepsy in cases where patients are medically refractory and are not candidates for surgical resection. This therapy has been shown to be effective in seizure reduction, yet very few patients achieve the ultimate goal of seizure freedom. Implantable neural stimulators (INSs) have many parameters that may be adjusted, and could be tuned to achieve very patient specific therapies. This study will develop a platform for stimulation setting optimization based on power spectral density (PSD) measures.
Gender: All
Ages: 18 Years - Any
Updated: 2025-10-24
1 state
NCT06304389
Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response. Light, and particularly blue light, can stimulate alertness, attention and cognition through modulation of anatomical targets which are common to the vagal afferent network. This project aims at understanding how exposure to blue enriched light may influence VNS effects in patients with refractory epilepsy by exploring the modulation of a series of biomarkers of VNS action. This could possibly lead to new therapeutic strategies to increase efficacy of VNS.
Gender: All
Ages: 18 Years - 60 Years
Updated: 2025-09-10
NCT05019885
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.
Gender: All
Ages: 18 Years - Any
Updated: 2025-08-15
1 state
NCT06524479
Investigating the Functional Characteristics During Wakefulness and Sleep Based on SEEG
This study aims to collect electrophysiological and clinical data from patients aged 14-65 with drug-resistant epilepsy who underwent SEEG. The collected data will be analyzed to investigate the functional connectivity during wakefulness and sleep states.
Gender: All
Ages: 14 Years - 65 Years
Updated: 2025-06-27
1 state
NCT06396494
An Automated Navigation System for Deep Brain Electrode Implantation
1. Analysis of the correlation between imaging and electrophysiological signals. 2. Real time analysis method for optimal implantation position. 3. Simultaneous Imaging and electrophysiology navigation. 4. Accuracy and security verification of navigation system. Expectation(Hypothesis): Develop an automated DBS surgical navigation system based on multimodal brain imaging data and neural electro-physiological signals, which can achieve real-time linkage navigation between imaging and electrophysiology, and automatically generate the optimal implantation position of DBS electrodes based on imaging and electrophysiological information through deep learning algorithms, thereby reducing DBS electrode implantation position errors and improving surgical efficacy.
Gender: All
Ages: 35 Years - 75 Years
Updated: 2024-05-02
1 state
NCT03644732
Atlas of Human Cognition by SEEG (MAPCOG-SEEG)
The main objective of MAPCOG\_SEEG is to create a database including brain recordings of cognition performed in clinical routine in patients during the pre-surgical SEEG assessment. This aims to be able to propose the first atlas of human cognition with a high temporal and spatial resolution.
Gender: All
Ages: 18 Years - 65 Years
Updated: 2024-03-19
NCT06241963
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy
To observe the clinical effect and safety of transcranial electrical stimulation on patients with refractory epilepsy before and after treatment and analyze its therapeutic mechanism.
Gender: All
Ages: 18 Years - 50 Years
Updated: 2024-02-20
1 state